CorMedix Stock Soars 20.26% on Strong Q1 Earnings

On April 8, 2025, CorMedix's stock surged by 20.26% in pre-market trading, reflecting a significant boost in investor confidence and market sentiment.

CorMedix Inc. recently announced its preliminary first-quarter 2025 results, showcasing a robust financial performance. The company reported unaudited net revenue of $39.0 million for the quarter, with expected adjusted EBITDA exceeding $22.5 million. This strong financial performance is attributed to larger-than-anticipated orders in late March and improved visibility into customer inventory levels.

Due to these positive developments, CorMedix has raised its H1 2025 net sales guidance to $62-70 million. While Q2 2025 sales are expected to be lower than Q1 due to shipment timing, patient utilization is forecast to grow throughout 2025, with H2 shipments projected to exceed H1. The company's cash position stands at $77.5 million as of March 31, 2025, providing significant liquidity for ongoing operations and planned clinical development.

CorMedix is also making strides in expanding its product offerings. The company plans to begin patient enrollment for DefenCath's Phase 3 study in Total Parenteral Nutrition (TPN) patients in late April. If approved, DefenCath's peak annual sales potential in this indication is estimated at $150-200 million, with a total addressable market of $500-750 million. This expansion into the TPN market represents a significant growth catalyst for the company, further validating DefenCath's value proposition and commercial strategy.